Recent Updates
Recently added Catalysts
INCY Positive Sentiment

Riassunto: I dati di Incyte al Congresso dell'Accademia Europea di Dermatologia e Venereologia (EADV) sottolineano l'ampiezza del portafoglio Infiammazione e Autoimmunità di Incyte

Tuesday, September 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Incyte announced that data from its Inflammation and Autoimmunity portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. The congress is scheduled for September 30 to October 3, 2026, in Vienna, Austria. The breadth of research to be presented underscores the strength of Incyte's portfolio in this area.

Market Sentiment Analysis

POSITIVE FACTORS

  • Incyte's portfolio shows a strong focus on inflammation and autoimmunity.
  • Data presentation at a significant European congress highlights research efforts.
  • The event will take place in a prestigious location, Vienna.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+31%
120-day peak, hindsight
Typical move
2.4%
average across 15 past catalysts
Lead asset
Ruxolitinib
Phase 2 · T-cell Lymphoma

Full Press Release Details

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) oggi ha reso noto che i dati provenienti dal suo portafoglio Infiammazione e Autoimmunità (IAI) verranno presentati al Congresso dell'Accademia Europea di Dermatologia e Venereologia (EADV, European Academy of Dermatology and Venereology) 2026, che si terrà dal 30 settembre al 3 ottobre 2026, a Vienna, Austria. "L'ampiezza della ricerca presentata all'EADV 2026 evidenzia la solidità del nostro portafoglio Infiammazione e Autoimmunità", ha

Frequently Asked Questions

When will Incyte present its data at EADV?

Incyte will present its data at the EADV Congress from September 30 to October 3, 2026.

Where is the EADV Congress 2026 taking place?

The EADV Congress 2026 will be held in Vienna, Austria.

What is the focus of Incyte's portfolio presented at EADV?

Incyte's portfolio presented at EADV focuses on inflammation and autoimmunity.

What does the breadth of research indicate?

The breadth of research highlights the strength of Incyte's portfolio in its field.

ShareAdd on Google
Tags: INCY Viatris Investor Conferences Healthcare Incyte EADV 2026 inflammation autoimmunity dermatology
Last updated: Sep 22, 2026

Biotech snapshot

Cash runway
$4536M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RuxolitinibPhase 2
T-cell Lymphoma →

Catalyst track record

+31%
best trade around INCY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for INCY.

See every catalyst's timing & PoA →